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Abstract A novel cDNA encoding a cysteine protease of the
papain family named cathepsin X was obtained by PCR
amplification from a human ovary cDNA library. The cathepsin
X cDNA is ubiquitously expressed in human tissues and contains
an open reading frame of 912 nucleotides encoding a predicted
protein of 303 amino acids. All highly conserved regions in
papain-like cysteine proteases including the catalytic residues are
present in cathepsin X. The mature part of cathepsin X is 26^
32% identical to human cathepsins B, C, H, K, L, O, S and W.
The cathepsin X sequence contains several unique features: (i) a
very short proregion; (ii) a three amino acid residue insertion in a
highly conserved region between the glutamine of the putative
oxyanion hole and the active site cysteine; and (iii) a second
insertion of 15 amino acid residues that can be aligned with the
occluding loop region in cathepsin B.
Published by Elsevier on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
Cysteine proteases of the papain family include the lysoso-
mal cathepsins B, C, H, L and S. The name ‘cathepsin’ is
derived from the Greek term meaning ‘to digest’ and was
initially introduced as a general term for digestive enzymes
with a slightly acidic pH optimum [1]. Later, only lysosomal
proteases were referred to as cathepsins and were thought to
function primarily in general intracellular protein degradation
and turnover within the endosomal/lysosomal system [2].
More recent ¢ndings suggest that in addition to protein deg-
radation, individual enzymes can ful¢ll speci¢c functions such
as proenzyme activation [3,4], antigen processing [5^7], hor-
mone maturation [8] and bone resorption [9,10]. Evidence has
been accumulating that cysteine proteases can also be secreted
and function extracellularly in pathophysiological processes
such as muscular dystrophy [11], arthritis [12], tumor invasion
and metastasis [13,14], and Alzheimer’s disease [15,16].
Among the lysosomal cysteine proteases, cathepsin S has at-
tracted recent interest. Its high elastinolytic activity in lung
macrophages at neutral pH raised the possibility that cathep-
sin S may be involved in macrophage-mediated tissue de-
struction [17]. Cathepsin S has also been demonstrated to
play an important role in MHC class II antigen processing
and to speci¢cally degrade the invariant chain Ii generating
CLIP peptides [6] and therefore targeted inhibition of this
enzyme may be bene¢cial for modulating MHC class II im-
mune responses. An additional role for cathepsin S in lung
biology, speci¢cally in cilial function, has been suggested but
functional studies have yet to be performed to test this hy-
pothesis [18]. Taken together, these ¢ndings clearly demon-
strate that cysteine proteases are important targets for inhib-
itor development.
Several novel members of this growing family have been
cloned recently, e.g. cathepsin O [19], cathepsin K [20^22]
and cathepsin W [23]. Among these, a speci¢c in vivo function
was demonstrated only for cathepsin K. Cathepsin K was
shown to be expressed at high levels in osteoclastomas [22]
and is a major enzyme in bone resorption [10]. Mutations in
the human cathepsin K gene were linked to pycnodysostosis,
an autosomal recessive osteochondrodysplasia [24]. However,
cathepsin K is also expressed in a variety of other tissues and
recent results showed a high level of cathepsin K expression in
human breast carcinoma [25]. Cathepsin O was initially iso-
lated from a breast cancer cDNA library, but then found to
be expressed in a variety of di¡erent tissues [19]. Cathepsin W
displays a more limited tissue distribution, restricted to lym-
phatic tissues [23]. A detailed characterization of these en-
zymes will provide further insight in their biological function
and potential therapeutical applications.
In this article we report the identi¢cation from the EST
(expressed sequence tags) database, cloning and tissue distri-
bution of a novel human cysteine protease of the papain fam-
ily, termed cathepsin X. The primary structure of cathepsin X
reveals strong homology to a cDNA clone isolated from bo-
vine heart encoding a short fragment corresponding to the C-
terminal region of a putative cysteine protease [26] and to two
sequences from Urechis caupo and Onchocerca volvulus [27,28].
Several unique features in the primary structure of cathepsin
X, such as a very short proregion or the position of cysteines,
suggest that it may belong to a new subfamily within the
papain family of cysteine proteases.
2. Materials and methods
2.1. Materials
Restriction endonucleases and T4 DNA ligase were purchased from
New England Biolabs. Human cDNA libraries, Northern blot and the
Advantage-GC cDNA Polymerase Mix were from Clontech Labora-
tories, Inc. (Palo Alto, CA, USA). Double-stranded DNA probes
were radiolabeled with 32P-dCTP (3000 Ci/mmol) using a commercial
random-priming kit (Ready-To-Go Labeling Kit, Amersham Pharma-
cia Biotech, Uppsala, Sweden). The vector pGEM-T was obtained
from Promega (Madison, WI, USA).
2.2. Identi¢cation and cloning of human cathepsin X
A TBLASTN search of the EST database maintained by the Na-
tional Center for Biotechnology Information (NCBI) was conducted,
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using peptide sequences derived from highly conserved regions in
papain-like cysteine proteases. A human EST clone (accession number
AA283747) was identi¢ed initially as a fragment of a novel gene
encoding the C-terminus of a putative papain-like cysteine protease.
The novel sequence was used in a second TBLASTN search and three
additional human clones with high similarity to the query sequence
were retrieved. Despite a poor sequence quality, it was possible to
align the new sequences using CLUSTALW and to compile a con-
sensus. The alignment was used to design a new query sequence up-
stream of the ¢rst one. The TBLASTN search, coupled with CLUS-
TALW alignment of the newly identi¢ed clones, was repeated ¢ve
times and yielded a total of 25 human and murine clones that most
likely belong to the same gene. The CLUSTALW alignments were
combined and a predicted sequence encoding part of a novel putative
cysteine protease of the papain family was generated. By using this
approach, it was possible to discriminate between the correct reading
frame and frameshifts due to sequencing errors. The compiled se-
quence did not include the 5P end of the novel cDNA. The full-length
cDNA was ampli¢ed by PCR from a human ovary cDNA library
(Marathon-Ready cDNA) using the Advantage-GC cDNA Polymer-
ase Mix (Clontech), the adaptor primer (5P-CCATCCTAATAC-
GACTCACTATAGGGC-3P) and a gene speci¢c antisense primer
(5P-TTAAACGATGGGGTCCCCAAATGTACAG-3P) derived from
the human EST clone (accession number AA283747). The obtained
1100-bp fragment was subcloned into the vector pGEM-T and se-
quenced using an automatic DNA sequencer (ABI PRISM 377, PE
Applied Biosystems, Foster City, CA, USA). A part of the 3P untrans-
lated region was obtained by PCR from the same library, using the
following sense primer: 5P-TACTTCCGCCGGGGACAGACCTGC-
TAC-3P.
2.3. Tissue distribution of cathepsin X
Normalized multiple tissue cDNA panels (Clontech) were screened
by PCR for an 830-bp fragment of the cathepsin X cDNA using
Advantage-GC cDNA Polymerase Mix (Clontech) and the two gene
speci¢c primers. Nested sense and antisense primers (5P-GGCCTCAT-
GAGTACCTGTCCCCAGC-3P and 5P-GCTCCTCGATGGCAAG-
GTTGTATCTGG-3P, respectively) were used in a second PCR reac-
tion to verify the initial PCR products. A human multiple tissue
Northern blot (Clontech) containing 2 Wg poly(A) RNA per lane
was probed with the 830-bp fragment of the cathepsin X cDNA,
labeled with 32P-dCTP by random priming as recommended by the
manufacturer. The blot was washed at high stringency (40 min with
2USSC, 0.05% SDS, 22‡C, 40 min with 0.1USSC, 0.1% SDS, 50‡C)
and exposed at 380‡C to a Kodak X-OMAT AR autoradiography
¢lm with 2 intensifying screens. The blot was stripped with boiling
SDS solution (0.5%) for 10 min and rehybridized with a L-actin probe
(Clontech) as described (data not shown).
3. Results and discussion
3.1. Human cathepsin X cDNA
A novel cDNA encoding a papain-like cysteine protease
that we have named cathepsin X was obtained by PCR am-
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Fig. 1. Nucleotide and predicted amino acid sequence of the human cathepsin X cDNA. Potential cleavage sites between the signal peptide and
the proregion and between the proregion and the mature form are indicated (R). The RGD motif is underlined, the two potential glycosylation
sites are double underlined. Numbers in parentheses correspond to the protein sequence. The proregion is numbered from 1p (N-terminus) to
38p (C-terminus) and the mature enzyme starts at residue number 1.
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pli¢cation from a human ovary cDNA library. The human
cathepsin X cDNA contains an open reading frame of 912
nucleotides encoding a predicted protein of 303 amino acids
(Fig. 1). A typical Kozak consensus [29] was found to sur-
round the initiating ATG codon. The stop codon is followed
by an extended non-translated 3P end. No polyadenylation site
was detected within the ¢rst 300 nucleotides 3P of the stop
codon. The deduced amino acid sequence contains a signal
peptide of 23 residues, using the ‘(33,31)-rule’ to identify
the cleavage site [30] and a proenzyme of 280 amino acid
residues. By analogy with other cysteine proteases, the puta-
tive processing site to the mature form of the enzyme has been
assigned to the Asp38p-Leu1 bond as shown in Fig. 1. Sequen-
ces derived from six independent PCR reactions were identi-
cal, except for two positions. In position 13p of the protein, a
proline to serine mutation was found, attributed to a C/T
mutation in nucleotide position 202. In addition, in position
68 an arginine or an alanine was observed, attributed to a
CG/GC mutation in nucleotide positions 481^482.
Human cathepsin X contains two potential N-glycosylation
sites at positions 123 and 163 (Fig. 1). The presence of a signal
sequence and potential glycosylation sites indicates that the
enzyme may be targeted to the endosomal/lysosomal compart-
ment via the mannose 6-phosphate receptor pathway. Inter-
estingly, the proregion of cathepsin X contains an integrin
binding motif Arg-Gly-Asp (RGD). RGD motifs in cell-adhe-
sive proteins such as ¢bronectin have been shown to serve as
ligand recognition sites for their cell-surface receptors, the
integrins. RGD sequences are also found in several serine
proteases such as pro-protein convertases, factor X and
thrombin as well as in cysteine proteases of the caspase fam-
ily, but are not present in other human cathepsins of the
papain family. Mutations within the RGD site in pro-protein
convertase (PC1) prevented autoprocessing of PC1 and al-
tered its intracellular tra⁄cking [31]. The RGD site in throm-
bin has been implicated in tumor-platelet adhesion and tumor
metastasis [32,33]. The function of the RGD motif in other
proteases is not known.
3.2. Tissue distribution
Cathepsin X expression was detected by PCR in various
normalized human cDNA libraries (Fig. 2) and found to be
expressed at medium to high levels in placenta, lung, liver,
kidney, pancreas, colon, ovary, peripheral blood leukocyte,
prostate, small intestine and spleen. Lower expression levels
were found in heart, brain, skeletal muscle, testis and thymus.
Since PCR based methods are considered to be highly sensi-
tive but less quantitative, cathepsin X was also detected by
Northern blot analysis (Fig. 3). A good correlation between
the amount of PCR product and the level of expression in the
corresponding Northern blot was observed within the 8 tissues
analyzed by both methods (Figs. 2 and 3). The approximate
size of the cathepsin X mRNA is 1.5 kb, as determined from
the Northern blot. Ubiquitous tissue distribution of cathepsin
X observed in this study does not exclude the possibility of a
specialized function. Cathepsin K, for example, was also
shown to be expressed in a variety of di¡erent tissues [22]
and found to play a more speci¢c role in osteoclastomas
[10,24].
3.3. Primary structure similarities and di¡erences to other
cysteine proteases
The highly conserved regions in papain-like cysteine pro-
teases including the catalytic residues (Cys31, His180) are
present in cathepsin X. Based on amino acid sequence align-
ment, the mature part of cathepsin X displays 26^32% identity
when compared to human cathepsins B, C, K, L, S, W and
papain. This clearly demonstrates that cathepsin X belongs to
the papain family of cysteine proteases (Fig. 4). BLASTP and
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Fig. 3. Northern blot analysis of human cathepsin X in human tis-
sues. A nitrocellulose blot was hybridized with a 32P-labeled cDNA
probe of human cathepsin X.
Fig. 2. Multiple tissue cDNA analysis of human cathepsin X. Normalized human multiple tissue cDNA panels were screened by PCR for an
830-bp fragment of the cathepsin X cDNA. After 30 cycles, samples were electrophoresed on a 2% agarose/EtBr gel: brain (1), heart (2), kid-
ney (3), liver (4), lung (5), pancreas (6), placenta (7), skeletal muscle (8), colon (9), ovary (10), peripheral blood leukocyte (11), prostate (12),
small intestine (13), spleen (14), testis (15), thymus (16), fetal brain (17), fetal heart (18), fetal kidney (19), fetal liver (20), fetal lung (21), fetal
skeletal muscle (22), fetal spleen (23), fetal thymus (24).
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BLASTN homology searches against protein and nucleotide
sequence databases revealed that cathepsin X shares a high
degree of similarity with a cDNA clone isolated from bovine
heart encoding the C-terminal region of a putative cysteine
protease (SWISS-PROT accession number: CATX_BOVIN)
[26]. This short fragment (73 amino acid residues) is 80%
identical to human cathepsin X and since this enzyme has
been termed cathepsin X, we used the same name for the
human homolog. Two additional sequences with 65^70%
identity to cathepsin X were identi¢ed in nucleotide databases,
one from the nematode Onchocerca volvulus (GenBank acces-
sion number U71150) and the other from the echiuran Urechis
caupo (GenBank accession number U30877). The O. volvulus
enzyme apparently is involved in molting of third stage larvae
[28]. These sequences most likely represent variants of the
same enzyme in di¡erent species.
The primary structure of cathepsin X contains several
unique features that clearly distinguish it from other human
cysteine proteases. The predicted proregion is very short (38
amino acid residues) compared to all known cathepsins. Pro-
regions of papain-like cysteine proteases vary in length and
range from 62 residues in cathepsin B to around 100 residues
in cathepsin L-like enzymes and 206 residues in cathepsin C.
In addition, the proregion of cathepsin X does not share a
signi¢cant degree of similarity with other cathepsins and in
particular, it does not contain the so-called ERFNIN motif,
present in cathepsin L-like cysteine proteases [34]. The prore-
gion of cathepsin X also contains a cysteine residue (Cys10p).
A cysteine residue in the proregion of cathepsin B has been
shown to contribute signi¢cantly to the inhibition of cathepsin
B by its propeptide [35]. Furthermore, a cysteine residue in the
proregion of cathepsin H plays an important role in de¢ning
the aminopeptidase activity of the enzyme [36]. Similarly, the
cysteine residue in the proregion of cathepsin X could play a
special role in regulation and/or catalytic activity. In addition,
cathepsin X contains 11 cysteine residues in the mature part
(including the putative active site cysteine Cys31) which may
form up to ¢ve disul¢de bonds. Based on a previously pub-
lished alignment [37] and structural data, the ¢rst two disul-
¢des (a and b in Fig. 4) are strictly conserved in all cysteine
proteases of the papain family and can be predicted for cath-
epsin X with a high level of con¢dence. The remaining seven
cysteines in cathepsin X may form up to three additional
disul¢de bonds. By analogy with cathepsin B, one of these
could involve two of the three cysteines within the 15 amino
acid residue insertion (c in Fig. 4).
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Fig. 4. Multiple amino acid sequence alignment of human cathepsin X with human cathepsins B, C, K, L, S, W and papain. Sequence informa-
tion is from SWISS-PROT (accession numbers CATB_HUMAN, CATC_HUMAN, CATK_HUMAN, CATL_HUMAN, CATS_HUMAN,
PAPA_CARPA) and from [23]. A previously published alignment was used as a template [37] and cathepsins K, W and X were aligned using
CLUSTALW. Active site residues are marked with *; predicted disul¢de connectivities are indicated by letters a^c; remaining cysteines are la-
beled with question marks.
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Another distinctive feature of cathepsin X is a three amino
acid residue insertion before the consensus CGXC (Cys28-
Gly29-Ser30-Cys31, Fig. 4). Such an insertion in a highly con-
served region between the glutamine (Gln22) of the putative
oxyanion hole and the active site cysteine is highly unusual for
a papain-like cysteine protease. A second relatively large in-
sertion of 15 amino acid residues can be aligned with the
occluding loop region in cathepsin B [38]. The occluding
loop in cathepsin B covers part of the SP subsites of the en-
zyme and was shown to be essential for the dipeptidyl
carboxypeptidase activity [39] and to interfere with the endo-
peptidase activity [40]. Two histidine residues (His110 and
His111) in this loop provide positively charged anchors for
the C-terminal carboxylate group of substrates. The insertion
in cathepsin X, however, does not contain histidines but other
ionizable groups are present and it remains to be determined
if any special function is associated with this insertion.
In conclusion, human cathepsin X is a new member of the
papain family of cysteine proteases. Unlike recently discov-
ered members of this family, which are closely related to cath-
epsin L, cathepsin X possesses a number of unique and inter-
esting features, which might confer special properties to the
enzyme. Preliminary data show that recombinant procathep-
sin X does not readily autoprocess at acidic pH. However, the
proenzyme is able to hydrolyze small synthetic substrates such
as Cbz-Phe-Arg-MCA (unpublished data). The precise biolog-
ical function of human cathepsin X is unclear. Its ubiquitous
tissue distribution and evolutionary conservation may indicate
an essential physiological role. Detailed biochemical charac-
terization as well as in vivo studies will provide clues to the
precise physiological role of cathepsin X and to its value as a
target for therapeutic intervention.
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